C. Zhou
Tongji University
30 Papers
53 Citations
C. Zhou is an academic researcher from Tongji University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 6, co-authored 26 publications.
Chat about Author
Papers
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
S.S. Ramalingam,Jhanelle E. Gray,Yuichiro Ohe,Byoung Chul Cho,Johan Vansteenkiste,C. Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,Riyaz Shah,K.H. Lee,Parneet Cheema,M. Tiseo,Thomas John,Meng-Chih Lin,Fumio Imamura,Rachel Hodge,Yuri Rukazenkov,Jean-Charles Soria,David Planchard +19 more
TL;DR: Osimertinib significantly improved OS vs comparator EGFR-TKI in the phase III FLAURA study, and the safety profile appears consistent with previously reported data.
68
Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))
Johan Vansteenkiste,Thanyanan Reungwetwattana,Kazuhiko Nakagawa,Byoung Chul Cho,M. Cobo Dols,E.K. Cho,Alessandro Bertolini,S Bohnet,C. Zhou,K.H. Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andrew P. Brown,Yuri Rukazenkov,S.S. Ramalingam +17 more
14
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)
Yuankai Shi,Lingqian Wu,Xianjun Yu,Puyuan Xing,Jiaojiao Zhou,A. Wang,Jufang Shi,Yali Hu,Zhenghang Wang,Guangyu An,Yong Fang,Sanyuan Sun,C. Zhou,C. Wang,Feng Ye,Xifei Li,J. Wang,M. Wang,Y. Liu,Yufen Zhao +19 more
TL;DR: The authors of this abstract have advised that full agreement between authors and sponsors on publication of the abstract has not been reached and they are therefore unable to publish this data at present.
5
1263pafatinib (a) followed by a + paclitaxel (p) or investigator's choice of single-agent chemotherapy (ic) in patients (pts) with advanced squamous cell carcinoma (scc) of the lung: subgroup analysis of lux-lung 5 (ll5)
K. Park,Jai Keun Kim,Martin Schuler,David Planchard,F. De Marinis,Yuh Min Chen,C. Zhou,Jaafar Bennouna,L. Xiaoqing,Ji Feng Feng,Paolo Bidoli,János Strausz,Christos Chouaid,Ming Shyan Huang,L. Ho,Bushi Wang,Vikram K. Chand,J.C.-H. Yang +17 more
TL;DR: In this small group of pts with SCC, the authors observed prolonged PFS, higher OR and trend towards longer OS in patients treated with A + P vs IC following A, and signs of activity in this difficult-to-treat population are encouraging.
5